[{"id":"f4f9a2d8-b043-402a-9f61-04b8bfdb4e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT00499122","created_at":"2021-01-18T01:47:12.687Z","updated_at":"2024-07-02T16:37:15.141Z","phase":"Phase 2","brief_title":"NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer","source_id_and_acronym":"NCT00499122","lead_sponsor":"University of Miami","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • NOV-002 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 06/04/2007","start_date":" 06/04/2007","primary_txt":" Primary completion: 04/01/2011","primary_completion_date":" 04/01/2011","study_txt":" Completion: 04/01/2011","study_completion_date":" 04/01/2011","last_update_posted":"2018-01-02"}]